Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330445 · ClinicalTrials.gov registry record · Phase 1
6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection
A Phase 1 study of Arthritis, Rheumatoid, sponsored by Protalex.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02330445: Completed Phase 1 study of Arthritis, Rheumatoid, sponsored by Protalex.
NCT02330445 is a Phase 1 study of Arthritis, Rheumatoid that has completed, run by Protalex. The registered enrollment target is 13 participants, below the 641-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330445, a Phase 1 study of Arthritis, Rheumatoid, has completed, sponsored by Protalex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Part A Primary Objective To determine the safety of six months of PRTX-100 administration. Part B Primary Objective To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies. Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100 treatment To evaluate the development of anti-PRTX-100 antibodies To explore feasibility of joint evaluations with ultrasound To explore feasibility of biomarkers as disease markers
Primary Outcome
Number, severity, and attribution of relatedness of Adverse Events will be analyzed.
Conditions Studied
Interventions
- DRUG PRTX-100
Study Locations (1)
Idaho
- Protalex Investigational Site - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-11-30 |
| Phase | Phase 1 |
What the finished NCT02330445 record still lists
NCT02330445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 641-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which PRTX-100 is the first listed.
NCT02330445 reports a single indexed study location in Idaho.
Frequently Asked Questions
What is clinical trial NCT02330445 about?
NCT02330445 is a clinical study titled "6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection". Part A Primary Objective To determine the safety of six months of PRTX-100 administration. Part B Primary Objective To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies. Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100 tr...
What is the current status of trial NCT02330445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-02. Estimated completion is 2016-11-30.
What conditions does trial NCT02330445 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT02330445?
The interventions under investigation include: PRTX-100 (DRUG).
Who is sponsoring clinical trial NCT02330445?
This trial is sponsored by Protalex, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330445 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02330445's enrollment target sits among peer trials
13 28th of 27 the lowest of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
Study To Evaluate The Pharmacokinetic Interaction Between PLA-695 And Methotrexate In Adults With Rheumatoid Arthritis
COMPLETED · Phase 1
-
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
COMPLETED · Phase 1
-
Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA
COMPLETED · Phase 1
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia